News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Sanofi and BI finalise swap to create market leading consume... Sanofi and BI finalise CHC and animal health swap
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Pharma looking to dual-action diabetes drugs to boost sales Pharma using FDA-mandated trials to give a commercial advantage.
News Diabetes drugs help Boehringer Ingelheim to grow Boehringer Ingelheim has posted a 4.1% rise in 2015 currency-adjusted sales, mainly thanks to a rapid acceleration in its diabetes drug revenues.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.